Russ Cohen

Most Popular

Exploring Undervalued Health Care Stocks Set to Rise Exploring Undervalued Health Care Stocks Set to Rise

For savvy investors, the current climate presents a unique chance to delve into the world of health care stocks that have been unjustly overlooked. These undervalued gems might just be ripe for the picking as they gear up to make a triumphant comeback.

One method to identify potential winners is through the Relative Strength Index (RSI), a tool that compares a stock’s performance on up days versus down days. When this indicator dips below 30, it typically signals that a stock is oversold, hinting at a potential upswing in the near future.

Without further ado, let’s dive into the top three health care stocks that are currently flashing attractive RSI signals, poised for a rebound.

Haemonetics Corporation – HAE

  • Haemonetics recently stunned investors with quarterly earnings that surpassed expectations. Despite this, the company’s stock has taken a tumble of approximately 19% over the past month, hitting a 52-week low of $70.74.
  • RSI Value: 25.47
  • HAE Price Action: Observant traders noted a 1.1% rise in Haemonetics’ shares, closing at $73.99 on the latest session.

Immunitybio Inc – IBRX

  • ImmunityBio made waves by revealing a promising study involving ANKTIVA alongside the AdHER2DC cancer vaccine as a potential treatment for endometrial cancer. Despite this groundbreaking news, the company’s stock has plunged by around 38% in the last month, hitting a 52-week low of $1.25.
  • RSI Value: 29.87
  • IBRX Price Action: In a surprising turn of events, Immunitybio’s stocks edged up by 2.6%, closing at $3.98 in the most recent trading session.

Progyny Inc – PGNY

  • Progyny Inc recently reported a disappointing second-quarter revenue, causing a stir among investors. Despite reassuring statements from CEO Pete Anevski regarding treatment demand, the company’s shares have seen a significant drop of approximately 31% in the last month, reaching a 52-week low of $19.60.
  • RSI Value: 29.06
  • PGNY Price Action: Mirroring a potential turnaround, Progyny saw a 1.7% surge in its shares, closing at $20.85 in the latest trading session.
See also  <!DOCTYPE html><html><head><title>The Impact of Trump's Policies on the Magnificent Seven Stocks</title></head><body><h2>Trump's Potential Impact on the Magnificent Seven Companies</h2><p>In the annals of American history, only one former president has managed to secure reelection after losing the first term - Grover Cleveland in 1892, a solitary figure in this political parable. Fast forward to the present, where former President Donald Trump is in a neck-and-neck race with Vice President Kamala Harris for the 2024 presidential throne. Should Trump emerge victorious, his policy decisions could cast a long shadow on the fortunes of the revered "Magnificent Seven" companies that include tech behemoths like Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla. An intriguing narrative unfolds as investors weigh their options in this high-stakes drama.</p><img alt="Former President Donald Trump." src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793603%2Ftrump-at-podium-image-source-official-white-house-photo-by-shealah-craighead.webp" style="width: 50%;"><p class="caption">Former President Donald Trump. Image source: Official White House Photo by Shealah Craighead.</p><h2>Assessing Trump's Proposals and Their Ramifications</h2><p>A trio of Trump's propositions loom large over the future of the Magnificent Seven, with his corporate tax cut scheme taking center stage. If re-elected, Trump vows to slice the federal corporate tax rate from the current 21% to a paltry 15%, a move that could recalibrate the financial landscape for these titans of industry. Tariffs are another cornerstone of his economic blueprint, with up to 20% levies on imports and a spotlight on China evident in his rhetoric. Moreover, Trump's zeal for deregulation, epitomized by a promise to scrap onerous rules at a 10:1 ratio against new regulations, could create seismic shifts, especially around artificial intelligence governance.</p><h2>Forecasting the Corporate Weather for the Magnificent Seven</h2><p>While a reduced tax burden might sound like sweet music to the ears of the Magnificent Seven, a deeper dive reveals a nuanced backdrop. Unveiling the effective tax rates paid by these giants in the last fiscal year paints a revealing picture. Alphabet, Amazon, Apple, Meta Platforms, Microsoft, and Nvidia all operate below the current 21% threshold, with Tesla even benefiting from a 50% tax boon, making the tax cut impact a mixed bag of fortunes.</p><p>Trump's tariff barrage could rattle the foundations of reliant companies, stirring debates on cost pass-through to consumers and the resultant sales pendulum. Apple's global supply chain stands vulnerable to the tariff storm, though players like Alphabet and Meta, deriving significant revenue from services, might weather the storm better.</p><p>The shadow of deregulation could sway fortunes in the cloudy skies of AI governance. Amazon, Microsoft, Alphabet, Nvidia, and to a lesser extent, Meta and Tesla, stand to gain from relaxed regulations, shaping a turbulent yet potentially rewarding horizon.</p><p>Trump's pointed criticism of Alphabet and Meta, juxtaposed with his favorable stance towards Microsoft and Nvidia, sets the stage for a strategic showdown where winners and losers are yet to emerge from the fog of political warfare.</p><h2>Identifying the Ripest Pick among the Magnificent Seven</h2><p>As the curtain rises on the looming political drama, the quest for the choicest investment amidst the Magnificent Seven intensifies. Microsoft and Nvidia emerge as prime contenders in this investment battleground. While Microsoft could reap the fruits of Trump's tax cuts due to its high tax rate and navigate the tariff headwinds, Nvidia's growth potential offers a tantalizing allure, promising the elixir of prosperity beyond the mirage of political turbulence. In the tumultuous landscape of Trumpian economics, the astute investor's choice between these icons could unfold as a pivotal journey towards prosperity.</p></body></html><html> <head> <title>Investment Insights: Assessing the Timing of Lucrative Opportunities</title> </head> <body> Investment Insights: Assessing the Timing of Lucrative Opportunities

These companies, once flying under the radar, may be on the cusp of a resurgence as market conditions shift. Keep a keen eye on these health care stocks as they gear up for a potential rebound in the coming weeks.

Read Next:


5 Stocks Our Experts Predict Could Double In the Next Year

By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.

Latest articles

Alibaba's Wan 3.0 AI Debut Follows $10.2B Share Sale: What's Ahead?

Russ Cohen

This $50 Trillion Robot Boom Starts on the Factory Floor

Russ Cohen

Elon Musk Predicts SpaceX Will Generate $3.5 Trillion in Revenue by 2033. History Suggests He Will Be Wrong Yet Again.

Russ Cohen